- Offer period from November 25 to December 24, 2013
- Offer price of CLP 332.48 per share
- Offer price represents a premium of 66.99% on the closing price of Sept 6
- Objective is to acquire all outstanding shares via tender offer
Aachen / Santiago de Chile, November 25, 2013. Inversiones Gruchi S.A., a subsidiary of Grünenthal GmbH Germany yesterday published its public tender offer for the purchase of all outstanding shares in Laboratorios Andrómaco S.A. (Securities Registry No. 704). Grünenthal offers CLP 332.48 per share in cash. The offer price represents a premium of 66.99% on the closing price of Sept 6, the last trading day before the disclosure of the agreement between major Laboratorios Andrómaco S.A. shareholders and Grünenthal.
Yesterday's launch of the tender offer followed the successful conclusion of an in-depth due diligence review of Empresas Andrómaco by Grünenthal. Prior to the due diligence, Grünenthal had reached an agreement with the two majority shareholders Inversiones NM Limitada and Moneda S.A. in which both shareholders have undertaken to tender their shares.
“Grünenthal is making a very attractive cash offer to Laboratorio Andrómaco's shareholders and we are pleased that Sergio Weinstein and Moneda support our bid. The tender offer gives shareholders an opportunity to secure a full valuation of their shares immediately. We are confident that shareholders will see the value and attractiveness of our offer and support the proposed transaction by tendering their shares”, said Oscar Ferenczi, Grünenthal’s Executive Vice President Latin America. The offer period will last from November 25 to December 24, 2013. The offer is conditional on Grünenthal being able to acquire at least 67% of the outstanding share capital as well as other customary closing conditions set out in the offer prospectus. The offer prospectus defining the terms and conditions of the tender offer has been published at http://www. grunenthal.cl and can be requested free of charge from IM Trust, Avenida Apoquindo 3721, Las Condes, Santiago or firstname.lastname@example.org.
Grünenthal has been active in Latin America since 1968 and today has affiliates in Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru and Venezuela and partner activities in Central America and the Caribbean In 2012, Grünenthal’s Latin America business recorded sales of USD 250 mn and employed more than 800 people. The Grünenthal Group achieved revenues of USD 1,251 mn and is headquartered in Aachen, Germany, with affiliates in 26 countries and employs approx. 4,400 employees worldwide.
IM Trust is serving as manager of the tender offer.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development.
Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of USD 1,251 mn.
More information: www.grunenthal.com.